TISIDB

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein. Cell junction, focal adhesion
Domain	PF01839 FG-GAP repeat PF00357 Integrin alpha cytoplasmic region PF08441 Integrin alpha
Function	The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB5 acts as a receptor for Adenovirus type C. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB5 and ITGAV:ITGB3 act as receptors for Coxsackievirus A9 and B1. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Herpes virus 8/HHV-8. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB6 acts as a receptor for herpes simplex 1/HHV-1. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Human parechovirus 1. ; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for West nile virus. ; FUNCTION: (Microbial infection) In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0001704 formation of primary germ layer GO:0001706 endoderm formation GO:0002474 antigen processing and presentation of peptide antigen via MHC class I GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0006816 calcium ion transport GO:0006869 lipid transport GO:0006909 phagocytosis GO:0007160 cell-matrix adhesion GO:0007229 integrin-mediated signaling pathway GO:0007369 gastrulation GO:0007492 endoderm development GO:0010742 macrophage derived foam cell differentiation GO:0010743 regulation of macrophage derived foam cell differentiation GO:0010745 negative regulation of macrophage derived foam cell differentiation GO:0010869 regulation of receptor biosynthetic process GO:0010871 negative regulation of receptor biosynthetic process GO:0010876 lipid localization GO:0010883 regulation of lipid storage GO:0010888 negative regulation of lipid storage GO:0016049 cell growth GO:0019058 viral life cycle GO:0019882 antigen processing and presentation GO:0019884 antigen processing and presentation of exogenous antigen GO:0019915 lipid storage GO:0030100 regulation of endocytosis GO:0030198 extracellular matrix organization GO:0030260 entry into host cell GO:0030335 positive regulation of cell migration GO:0031589 cell-substrate adhesion GO:0032368 regulation of lipid transport GO:0032369 negative regulation of lipid transport GO:0032799 low-density lipoprotein receptor particle metabolic process GO:0032800 receptor biosynthetic process GO:0033627 cell adhesion mediated by integrin GO:0033687 osteoblast proliferation GO:0033688 regulation of osteoblast proliferation GO:0033690 positive regulation of osteoblast proliferation GO:0034113 heterotypic cell-cell adhesion GO:0034446 substrate adhesion-dependent cell spreading GO:0035635 entry of bacterium into host cell GO:0035821 modification of morphology or physiology of other organism GO:0035987 endodermal cell differentiation GO:0038027 apolipoprotein A-I-mediated signaling pathway GO:0038034 signal transduction in absence of ligand GO:0040017 positive regulation of locomotion GO:0042157 lipoprotein metabolic process GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I GO:0043062 extracellular structure organization GO:0043112 receptor metabolic process GO:0043277 apoptotic cell clearance GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044003 modification by symbiont of host morphology or physiology GO:0044068 modulation by symbiont of host cellular process GO:0044409 entry into host GO:0045713 low-density lipoprotein particle receptor biosynthetic process GO:0045714 regulation of low-density lipoprotein particle receptor biosynthetic process GO:0045715 negative regulation of low-density lipoprotein particle receptor biosynthetic process GO:0045785 positive regulation of cell adhesion GO:0045807 positive regulation of endocytosis GO:0046718 viral entry into host cell GO:0048002 antigen processing and presentation of peptide antigen GO:0048010 vascular endothelial growth factor receptor signaling pathway GO:0048514 blood vessel morphogenesis GO:0050746 regulation of lipoprotein metabolic process GO:0050748 negative regulation of lipoprotein metabolic process GO:0050764 regulation of phagocytosis GO:0050766 positive regulation of phagocytosis GO:0050900 leukocyte migration GO:0050919 negative chemotaxis GO:0051051 negative regulation of transport GO:0051235 maintenance of location GO:0051272 positive regulation of cellular component movement GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0052066 entry of symbiont into host cell by promotion of host phagocytosis GO:0052190 modulation by symbiont of host phagocytosis GO:0052191 positive regulation by symbiont of host phagocytosis GO:0052231 modulation of phagocytosis in other organism involved in symbiotic interaction GO:0052370 entry of organism into cell of other organism by promotion of phagocytosis in other organism involved in symbiotic interaction GO:0052522 positive regulation by organism of phagocytosis in other organism involved in symbiotic interaction GO:0060627 regulation of vesicle-mediated transport GO:0070371 ERK1 and ERK2 cascade GO:0070588 calcium ion transmembrane transport GO:0070838 divalent metal ion transport GO:0072511 divalent inorganic cation transport GO:0090077 foam cell differentiation GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:2000147 positive regulation of cell motility GO:2000425 regulation of apoptotic cell clearance GO:2000535 regulation of entry of bacterium into host cell GO:2000536 negative regulation of entry of bacterium into host cell GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function	GO:0001618 virus receptor activity GO:0001846 opsonin binding GO:0001968 fibronectin binding GO:0002020 protease binding GO:0005080 protein kinase C binding GO:0005216 ion channel activity GO:0005244 voltage-gated ion channel activity GO:0005245 voltage-gated calcium channel activity GO:0005261 cation channel activity GO:0005262 calcium channel activity GO:0005520 insulin-like growth factor binding GO:0015026 coreceptor activity GO:0015085 calcium ion transmembrane transporter activity GO:0015267 channel activity GO:0017134 fibroblast growth factor binding GO:0019838 growth factor binding GO:0019955 cytokine binding GO:0019956 chemokine binding GO:0019960 C-X3-C chemokine binding GO:0022803 passive transmembrane transporter activity GO:0022832 voltage-gated channel activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0022843 voltage-gated cation channel activity GO:0031994 insulin-like growth factor I binding GO:0038132 neuregulin binding GO:0046873 metal ion transmembrane transporter activity GO:0050431 transforming growth factor beta binding GO:0050840 extracellular matrix binding GO:0072509 divalent inorganic cation transmembrane transporter activity GO:1990430 extracellular matrix protein binding
Cellular Component	GO:0001726 ruffle GO:0005902 microvillus GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0008305 integrin complex GO:0009897 external side of plasma membrane GO:0030027 lamellipodium GO:0030055 cell-substrate junction GO:0030139 endocytic vesicle GO:0030175 filopodium GO:0031252 cell leading edge GO:0031253 cell projection membrane GO:0031256 leading edge membrane GO:0031258 lamellipodium membrane GO:0031527 filopodium membrane GO:0031528 microvillus membrane GO:0032587 ruffle membrane GO:0034683 integrin alphav-beta3 complex GO:0034684 integrin alphav-beta5 complex GO:0034686 integrin alphav-beta8 complex GO:0035867 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0043235 receptor complex GO:0045335 phagocytic vesicle GO:0098552 side of membrane GO:0098636 protein complex involved in cell adhesion GO:0098802 plasma membrane receptor complex GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome hsa04151 PI3K-Akt signaling pathway hsa04510 Focal adhesion hsa04512 ECM-receptor interaction hsa04514 Cell adhesion molecules (CAMs) hsa04810 Regulation of actin cytoskeleton hsa04919 Thyroid hormone signaling pathway
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-1236975: Antigen processing-Cross presentation R-HSA-422475: Axon guidance R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1236973: Cross-presentation of particulate exogenous antigens (phagosomes) R-HSA-1266738: Developmental Biology R-HSA-3000178: ECM proteoglycans R-HSA-1566948: Elastic fibre formation R-HSA-1474244: Extracellular matrix organization R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-216083: Integrin cell surface interactions R-HSA-373760: L1CAM interactions R-HSA-3000157: Laminin interactions R-HSA-2129379: Molecules associated with elastic fibres R-HSA-6798695: Neutrophil degranulation R-HSA-3000171: Non-integrin membrane-ECM interactions R-HSA-210990: PECAM1 interactions R-HSA-162582: Signal Transduction R-HSA-445144: Signal transduction by L1 R-HSA-194138: Signaling by VEGF R-HSA-3000170: Syndecan interactions R-HSA-4420097: VEGFA-VEGFR2 Pathway

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04145 Phagosome
hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04514 Cell adhesion molecules (CAMs)
hsa04810 Regulation of actin cytoskeleton
hsa04919 Thyroid hormone signaling pathway

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-422475: Axon guidance
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1236973: Cross-presentation of particulate exogenous antigens (phagosomes)
R-HSA-1266738: Developmental Biology
R-HSA-3000178: ECM proteoglycans
R-HSA-1566948: Elastic fibre formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-216083: Integrin cell surface interactions
R-HSA-373760: L1CAM interactions
R-HSA-3000157: Laminin interactions
R-HSA-2129379: Molecules associated with elastic fibres
R-HSA-6798695: Neutrophil degranulation
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-210990: PECAM1 interactions
R-HSA-162582: Signal Transduction
R-HSA-445144: Signal transduction by L1
R-HSA-194138: Signaling by VEGF
R-HSA-3000170: Syndecan interactions
R-HSA-4420097: VEGFA-VEGFR2 Pathway

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ITGAV and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ITGAV in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -3.02; FDR: 0.02000	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.47; FDR: 0.01650	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ITGAV in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.11	0.813
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.646	0.776
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.295	0.842
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.216	0.38
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.418	0.859
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.042	0.989
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.294	0.57
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.328	0.879
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.242	0.921
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.383	0.825
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.83	0.754
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.289	0.0046

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ITGAV in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	7.4	-2.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	14.3	-14.3	0.209
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGAV. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGAV. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGAV. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGAV. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ITGAV expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ITGAV and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ITGAV
Name	integrin, alpha V
Aliases	CD51; VNRA; MSK8; VTNR; antigen identified by monoclonal antibody L230; vitronectin receptor; integrin, alph ......
Chromosomal Location	2q31-q32
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ITGAV collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ITGAV.

ID	Name	Drug Type	Targets	#Targets
DB00098	Antithymocyte immunoglobulin (rabbit)	Biotech	CD1A, CD4, CD86, FCGR2B, ITGAL, ITGAV, ITGB1, ITGB3, MR1	9

Browse ITGAV